The Neuroscience of Inclusion and Diversity: Unlocking High-Impact Team Performance
NORTHAMPTON, MA / ACCESSWIRE / October 29, 2024 / Diversity and inclusion are not only core elements of Teva's cultural...
Neuroscience
QuantalX Introduces a Breakthrough in the Diagnosis and Classification of Parkinson’s Disease
NEW YORK, Oct. 29, 2024 /PRNewswire/ -- QuantalX Neuroscience, a leader in objective neurodiagnostic technology, announces a significant discovery in the...
BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024
BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as...
Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy
LOS ANGELES, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports that the United States Food and Drug Administration (FDA)...
BioXcel Therapeutics to Present at ThinkEquity Conference
NEW HAVEN, Conn., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence...
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics...
Linus Health to Demonstrate How Digital Health Powers Innovation at Clinical Trials on Alzheimer’s Disease (CTAD)
Leaders to deliver four poster presentations showing how its digital health platform lowers investigator burden, enables precision recruitment, and delivers...
MIRA Pharmaceuticals’ Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be Presented at...
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”)...
Vitamin K supplement slows prostate cancer in mice
COLD SPRING HARBOR, N.Y., Oct. 24, 2024 /PRNewswire/ -- Prostate cancer is a quiet killer. In most men, it's treatable....
Lin Health to Collaborate with Mayo Clinic to Expand Access to Evidence-Based, Tech-Enabled Chronic Pain Care
Retraining the brain's neural circuitry through a behavioral health approach empowers people living with chronic pain to avoid costly and...
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
MIAMI, FL / ACCESSWIRE / October 21, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is...
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is...
Nikon Small World Competition Celebrates 50 Years with Groundbreaking Image of Brain Tumor Cells
Celebrating its golden anniversary, Nikon Small World honors a stunning photo of brain tumor cell structures, advancing our understanding of...
Linus Health Leader to Join ‘Brainiacs’ Panel at HLTH 2024 to Discuss Advancements in Cognitive Impairment Screening
Company also a finalist for Digital Health Awards to be announced on opening night BOSTON, Oct. 17, 2024 /PRNewswire/ --...
Sarah Sheikh Joins Cerevance’s Board of Directors
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment...
Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints
– Topline results from Phase 2a study – Nearly 60% of all patients treated with gemlapodect and 88% of patients...
Monument Therapeutics Secures £1M Investment to Fund Its Schizophrenia Programme And Drive Next Stage of Growth
MANCHESTER, England, Oct. 15, 2024 /PRNewswire/ -- Monument Therapeutics, a precision neuroscience company, today announced a further £1M equity investment...